This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Abstract
A vaccine that targets tumor neoantigens may improve the effectiveness of nivolumab. A trial that included patients with metastatic melanoma, non–small cell lung cancer, and bladder cancer found that progression-free survival was longer than in historical controls. The vaccine also stimulated tumor-specific T cells.
- ©2019 American Association for Cancer Research.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't.
September 2019
Volume 9, Issue 9
Volume 9, Issue 9
Vaccine Increases PFS for Metastatic Tumors
Jump to section
Advertisement